Amgen (AMGN) Reports Positive Phase 3 TEZSPIRE Results In Eosinophilic Esophagitis

Amgen (NasdaqGS:AMGN) and AstraZeneca reported positive full Phase 3 results for TEZSPIRE in eosinophilic esophagitis (EoE). The Phase 3 trial showed significant and clinically meaningful improvements in EoE symptoms and endoscopic endpoints sustained through one year. Investigators reported a favorable safety profile for TEZSPIRE in this EoE study population of patients with limited treatment options. The TEZSPIRE Phase 3 EoE data lands alongside wider findings from our research on Amgen's...